Tenaya Therapeutics price target lowered to $3 from $5 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $3 from $5 and keeps a Buy rating on the shares. The firm cites dilution from the equity raise for the target drop. The interim TN-401 update demonstrates clinical proof-of-concept with further updates expected in the first half of 2026, the analyst tells investors in a research note.